secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017880
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q1 revenue $63M (down 95% YoY); net loss $140.9M; new CEO Marianne De Backer
--------------------------------------------------------------------------------

- Q1 2023 total revenues $63M vs $1.2B in Q1 2022 (-94.9%); net loss of $140.9M ($1.06/sh) vs net income of $518.6M.
- Cash, equivalents, and investments $2.3B at March 31; anticipates ~$272M payment to GSK in Q2 2023 for excess sotrovimab.
- Marianne De Backer joined as CEO in April 2023; Sung Lee appointed EVP & CFO in March 2023.
- Pipeline: Phase 2 data readouts for influenza (mid-2023), hepatitis B (2023), hepatitis D (H2 2023); $10M Gates Foundation grant for HIV vaccine trial.
- R&D expenses rose to $157.6M (up 75% YoY) driven by VIR-2482 influenza antibody program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/0000950170-23-017880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000095017023017880/vir-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer